Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athenex Inc ATNXQ

Healthcare Biotechnology
Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is... see more

Recent & Breaking News (GREY:ATNXQ)

Athenex, Inc. Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis

GlobeNewswire September 25, 2017

Athenex, Inc. Added to Russell 2000® and Russell 3000® Indexes

GlobeNewswire September 18, 2017

CORRECTING and REPLACING: Athenex, Inc.

GlobeNewswire September 11, 2017

ContraVir Pharmaceuticals Receives HBV IND Approval for Tenofovir Exalidex (TXL™) in the United States

GlobeNewswire September 11, 2017

Athenex Pharmaceutical Division and SunGen Pharma Announce Terbutaline Sulfate Injection Product Launch

GlobeNewswire August 31, 2017

Athenex, Inc. Announces Second Quarter 2017 Results

GlobeNewswire August 14, 2017

Athenex Announces Recent Product Launches in Commercial Business

GlobeNewswire August 1, 2017

Athenex, Inc. to Report Second Quarter 2017 Earnings Results on August 14, 2017

GlobeNewswire July 31, 2017

Athenex, Inc. Announces Approval of Tax Incentives from State of New York for the Dunkirk Facility

GlobeNewswire July 27, 2017

Athenex, Inc. Announces Commencement of Patient Enrollment for Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer

GlobeNewswire July 19, 2017

Athenex Pharmaceutical Division Receives FDA Clearance to Import Sodium Bicarbonate 8.4% Injection to Address U.S. Drug Shortage

GlobeNewswire July 12, 2017

Athenex, Inc. Announces Submission of Investigational New Drug Application of Oraxol to Chinese FDA

GlobeNewswire July 5, 2017

Athenex, Inc. Announces Closing of Initial Public Offering and Full-Exercise of Over-Allotment Option

GlobeNewswire June 19, 2017

Nasdaq Welcomes Athenex, Inc. (Nasdaq: ATNX) to The Nasdaq Stock Market

GlobeNewswire June 14, 2017

Athenex, Inc. Announces Pricing of Initial Public Offering

GlobeNewswire June 14, 2017

Athenex, Inc. (Nasdaq: ATNX) to Ring The Nasdaq Stock Market Closing Bell in Celebration of Its IPO

GlobeNewswire June 14, 2017